Carboplatin

NCCN began measuring drug shortfalls more than 3 years ago; today 96% of leading academic centers surveyed say the problem persists. 94% of centers surveyed noted a current shortage of ifosfamide, in addition to a return of carboplatin shortages in 71%. PLYMOUTH MEETING, Pa., Sept. 10, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—published updated data on the current impact of generic cancer medication shortages in the United States. The data comes from survey responses from pharmacy directors and other clinical and administrative leadership at NCCN Member Institutions from late August. According to the results, 100% of responding cancer centers are experiencing a shortage for at least one anti-cancer agent; with more than 20% of centers currently in shortage for five or more different medications. Continue Reading 100% of responding cancer centers are experiencing a shortage for at least one anti-cancer agent. Post this Visit NCCN.org/drug-shortages to view results from the latest survey. Of the responding centers, 94% noted a shortage of ifosfamide, a generic chemotherapy that is used in treatment for a variety of cancers, including bladder, ovarian, testicular, uterine, soft tissue sarcoma, osteosarcoma, and several adult and pediatric leukemias and lymphomas. In addition, 71% of centers noted a shortage of carboplatin and 16% for cisplatin, which are key chemotherapies used as the backbone of regimens to treat numerous different tumor types. The immunotherapy Bacillus Calmette-Guérin (BCG) for bladder cancer was also in short supply for more than half of the respondents. NCCN first started surveying Member Institutions about drug shortage issues during concerns about a lack of carboplatin and cisplatin in June 2023. Results from the latest survey and previous surveys, are available at NCCN.org/drug-shortages . When asked if national or state policies have made the issue of drug shortages better or worse since 2023, 4% of pharmacy directors surveyed said it has gotten better, while 96% felt it stayed the same. "It is disheartening that we remain in the same situation, including recurring or continued shortages of some drugs, despite years of raising the alarm and providing insight about this disruptive and dangerous issue for cancer care in America," said Crystal S. Denlinger, MD, Chief Executive Officer, NCCN. "The good news is the cancer centers in our network have developed internal strategies, task forces, and communications plans for keeping patient care and clinical trials on track. The bad news is that this takes time and attention that could be better spent on improving patient experiences and outcomes and adds additional stress to an already burdened system." When asked how they are handling these shortages, 61% of responding centers noted they required pharmacy and physician-led mitigation strategies in order to keep all of their patients on a recommended dose and schedule, with the majority implementing waste management strategies, while others explored alternative recommended regimens to deliver guideline-recommended care. When treatment plans had to be modified, 90% of centers noted a need for repeat prior authorization of the plan, significantly increasing the amount of work per patient and adding in the potential for a delay in care continuity. "Nearly every pharmacy director who responded to our survey would like to see economic incentives put in place to encourage high-quality manufacturing for generic cancer medications," noted Alyssa Schatz, DrPh, MSW, Vice President of Policy & Advocacy, NCCN. "That is something that advocates have been requesting for years. As one respondent noted: 'many oncology generics are clinically indispensable but economically unattractive. Without correcting that economic imbalance, shortages are likely to recur.' The survey results also illuminated a desire for better information around generics suppliers and requests for earlier notifications by manufacturers to FDA." NCCN is part of the End Cancer Drug Shortages Coalition which brings together more than a dozen hematology/oncology nonprofits to address this issue and suggest long-term solutions. The group put out a consensus statement in May 2026 with a big picture look at the ongoing problem and a list of policy proposals for the future. Visit NCCN.org/drug-shortages to learn more. About the National Comprehensive Cancer Network The National Comprehensive Cancer Network® (NCCN ®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to defining and advancing quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) provide transparent, evidence-based, expert consensus-driven recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the National Comprehensive Cancer Network Foundation (NCCNF). NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information. Media Contact: Rachel Darwin 267-622-6624 [email protected] SOURCE National Comprehensive Cancer Network 21% more press release views with Request a Demo

Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel New York in New York City on Wednesday, September 23, 2026, beginning at 10:00 a.m. ET. To register to attend the event in person or virtually, please RSVP by clicking here . "We look forward to gathering with investors and scientific leaders to showcase key progress across our IMNN-001 clinical program," said Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON. "With our Phase 3 OVATION 3 trial advancing and insightful data emerging from our Phase 2 MRD study, this event highlights our commitment to redefining treatment paradigms for women facing advanced ovarian cancer. A highlight of the event will be a conversation with an OVATION 1 clinical trial participant who received IMNN-001 in the study." The event will feature a conversation with an OVATION 1 clinical trial participant offering a firsthand perspective on her experience in the study and in the years following the trial. Presentations will include leading experts in ovarian cancer and principal investigators involved in the Company's Phase 3 OVATION 3 clinical trial and the Phase 2 minimal residual disease (MRD) clinical trial, conducted in partnership with the Break Through Cancer Foundation. Members of IMUNON's management team will join these experts to deliver updates on new IMNN-001 data and discuss the potential role of IMNN-001 in transforming the treatment landscape for women with advanced ovarian cancer. A live Q&A session and networking opportunities will follow the formal presentations. Featured Presentations and Speakers: Redefining Frontline Care — Unlocking the Potential of a First-in-Class IL-12 Immunotherapy in Ovarian Cancer Presenter: Stacy R. Lindborg, Ph.D., President and Chief Executive Officer, IMUNON, Inc. Resurrecting IL-12: Overcoming Historical Barriers with Targeted TheraPlas ™ Delivery of IMNN-001 Presenter: Douglas V. Faller, M.D., Ph.D., Chief Medical Officer, IMUNON, Inc. Unveiling Translational Insights — MRD Clearance, Microenvironment Remodeling, and Combination Strategies Presenter: Amir Jazaeri, M.D., Vice Chair for Clinical Research, Director, Gynecologic Cancer Immunotherapy Program, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center Advancing Frontline Efficacy — Translating OVATION 2 Overall Survival Signals into Pivotal Phase 3 OVATION 3 Presenter: Premal H. Thaker, M.D., David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology, Chief of Gynecologic Oncology, Director of Gynecologic Oncology Clinical Research, Professor in Gynecologic Oncology, Washington University School of Medicine Beyond the Data: Clinical Experience with IMNN-001 — A Conversation with an OVATION 1 Study Participant Presenter: OVATION 1 clinical trial participant, with William Bradley, M.D., Professor and Vice Chair for Clinical Research, Division of Gynecologic Oncology, Medical College of Wisconsin Building the Future — Strategic Milestones, Catalysts, and the Investment Horizon Presenter: Stacy R. Lindborg, Ph.D., President and Chief Executive Officer, IMUNON, Inc. About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas ® platform technology, IMNN-001 is an IL-12 DNA plasmid encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local production of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel neoadjuvantly in patients with newly diagnosed ovarian cancer. IMUNON previously reported positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m² administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (N/ACT) of paclitaxel and carboplatin compared to standard-of-care N/ACT alone in 112 patients with newly diagnosed advanced ovarian cancer. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The first modality, TheraPlas ® , is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in the ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 is designed to instruct the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit . Forward-Looking Statements IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding expectations regarding the timing and enrollment of the Company's clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company's products, if approved, the potential efficacy and safety pro our product candidates, and the Company's plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON's filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise. Investors Contact: Valter Pinto KCSA Strategic Communications 212-896-1254 imunon@kcsa.com